Immune Function Tests for Hazard Identification: A Paradigm Shift in Drug Development
نویسندگان
چکیده
منابع مشابه
Reverse Pharmacology-A Paradigm Shift for Drug Discovery and Development
Corresponding Author: Ashok D.B. Vaidya Kasturba Health Society, Advanced Centre of Reverse Pharmacology (ICMR) 17, Khandubhai Desai Road, Vile Parle (West), Mumbai, 400 056, India Email: [email protected] Abstract: The current scenario of drug discovery and development is facing a model perturbation, despite significant advances in genomics, proteomics, metabolomics, combinatorial chemistry and...
متن کاملCancer immunotherapy trials: leading a paradigm shift in drug development
Background Cancer immunotherapy has a long history in the clinic. William Coley was an orthopedic surgeon in the late 1800’s who noted marked tumor regression in a patient with severe erysipelas. Based on this observation, he hypothesized that stimulating the immune system could effectively treat cancer. Thus, over the next decades he gave various bacterial products, including live bacteria, to...
متن کاملA Methodology for Paradigm Shift to Explain Sustainable University
The sustainable university concept is rooted in prevalent paradigms pertained to economic, social and environmental development, which all focus on systemic thought and rationality; besides, they tend to discover and solve problems by applying an interdisciplinary approach. However, the epistemic component is what these paradigms have ignored. The purpose of this study is to explain a methodo...
متن کاملThe paradigm shift to an “open” model in drug development
The rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent protection, decrease reimbursement, and the recession have made it more difficult for the pharmaceutical and biotechnology industry to develop drugs. Due to the unsustainable amount of time and money in developing a drug that will have a significant return on investment (ROI) it ...
متن کاملA paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens.
Multidrug-resistant (MDR) gram-negative pathogens pose a major threat to patients worldwide. Although the organisms remain relatively uncommon overall, their incidence is steadily increasing with associated increases in mortality and pharmacoeconomic impact. As evidenced by the dearth of new products in the pipeline or in clinical use, the conventional paradigm for the development of drugs agai...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology
سال: 2006
ISSN: 1742-7835,1742-7843
DOI: 10.1111/j.1742-7843.2006.pto_374.x